info@RegenProtocols.com
561-325-7000
141 NW 20th St., Suite G1 Boca Raton, FL 33431
A targeted regenerative framework that supports nerve repair and reduces chronic neuropathic pain signaling with neurotrophic peptides and mitochondrial support.
A targeted regenerative framework for neuropathic pain and peripheral nerve injury. The protocol combines neurotrophic support peptides, mitochondrial stabilizers, immune modulators, and regulators of central sensitization to promote nerve repair while reducing chronic neuropathic pain signaling.
The goal is to interrupt pain chronification, restore neuronal integrity, and improve functional neurological recovery.
| Agent | Route | Dose | Frequency | Duration |
|---|---|---|---|---|
| BPC-157 | SubQ | 500 mcg | Twice daily | 8–12 weeks |
| ARA-290 | SubQ | 2–4 mg | Three times weekly | 8–12 weeks |
| SS-31 | SubQ | 1.0 mg | Daily | 8 weeks |
| Selank | Intranasal | 400 mcg | Twice daily | 4–8 weeks |
| KPV | SubQ | 500 mcg | Daily | 6–8 weeks |
ARA-290 is the centerpiece of this protocol. It is an innate repair receptor (IRR) agonist derived from erythropoietin, and it promotes nerve repair and reduces neuropathic pain through non-opioid pathways.
BPC-157 provides neurotrophic support and has shown reparative effects in preclinical nerve injury models. SS-31 stabilizes neuronal mitochondrial membranes and reduces oxidative stress, a key contributor to the chronification of neuropathic pain. Selank modulates GABAergic signaling and reduces central sensitization. KPV supports inflammatory regulation without broad immunosuppression.
